Effects of dapagliflozin on body weight in patients with type 2 diabetes mellitus: Evidence‑based practice

Yan Han; Ya-Feng Li; Chao-Wei Ye; Yao-Yang Gu; Xiao Chen; Qian Gu; Qiang-Qiang Xu; Xian-Ming Wang; Su-Mei He; Dong-Dong Wang

doi:10.3892/etm.2024.12461

Effects of dapagliflozin on body weight in patients with type 2 diabetes mellitus: Evidence‑based practice

Exp Ther Med. 2024 Feb 28;27(4):173. doi: 10.3892/etm.2024.12461. eCollection 2024 Apr.

Authors

Yan Han¹, Ya-Feng Li², Chao-Wei Ye³, Yao-Yang Gu³, Xiao Chen⁴, Qian Gu³, Qiang-Qiang Xu³, Xian-Ming Wang³, Su-Mei He⁵, Dong-Dong Wang³

Affiliations

¹ Department of Emergency Medicine, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221116, P.R. China.
² Department of Pharmacy, Feng Xian People's Hospital, Xuzhou, Jiangsu 221700, P.R. China.
³ Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China.
⁴ School of Nursing, Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China.
⁵ Department of Pharmacy, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, Jiangsu 215153, P.R. China.

Abstract

The dose-dependent pharmacological response to dapagliflozin in patients with type 2 diabetes mellitus (T2DM) with regard to weight loss remain unknown. The aim of the present study was to investigate the effects of dapagliflozin on weight loss in patients with T2DM. A total of 8,545 patients with T2DM from 24 randomized controlled trials reported in the literature were selected for inclusion in the study. Data from these trials were analyzed using maximal effect (E_max) models with nonlinear mixed effects modeling; the evaluation index was the body weight change rate from baseline values. Patients treated with 2.5 mg/day dapagliflozin exhibited an E_max of -3.04%, and the time taken for therapy to reach half of the E_max (ET₅₀) was estimated to be 30.8 weeks for patients treated with this dose. Patients treated with 5, 10 and 20 mg/day dapagliflozin exhibited E_max values of -6.57, -4.12 and -3.23%, respectively, and their ET₅₀ values were estimated to be 27.3, 20.4 and 4.23 weeks, respectively. The data indicated ideal linear relationships between individual predictions and observations, suggesting the optimal fitting of the final models. The present study is the first systematic analysis of the effect of dapagliflozin on weight loss in patients with T2DM. The application of dapagliflozin at 5 mg/day exhibited a greater weight loss effect compared with the other doses used, and the weight loss onset time shortened as the dose of dapagliflozin increased.

Keywords: dapagliflozin; effect; evidence-based practice; type 2 diabetes mellitus; weight loss.

Grants and funding

Funding: The study was supported by The Innovative Practice Training Program for Students of Jiangsu Higher Education Institutions (grant no. 202210313053Z), The National Innovative Practice Training Program for Students of Higher Education Institutions (grant no. 202210313053), The Xuzhou Special Fund for Promoting Scientific and Technological Innovation (grant no. KC21257), The Initializing Fund of Xuzhou Medical University (grant nos. RC20552111 and RC20552222), The Fusion Innovation Project of Xuzhou Medical University (grant nos. XYRHCX2021011 and XYRHCX2022005), Jiangsu Province Education Science Planning Project (grant no. C/2022/01/36), Xuzhou Medical University Labor Education Special Support Project (grant no. X1d202209), Jiangsu Province Higher Education Informatization Research Topic (grant no. 2023JSETKT136) and Xuzhou Medical University Research Topic of Higher Education Teaching Reform (grant no. Xjyzrd202304).